http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
YHB216의 토끼에서 국소독성시험 및 마우스에서 소핵시험
강민정,김미영,박명규,김봉태,안경규,최연식,문병석,이종욱 한국독성학회 2002 Toxicological Research Vol.18 No.1
YHB216 is one of new recombinant human erythropoietins (rHu-EPO) developed by Yuhan Research Institute. The rHu-EPO products are widely being used for the treatment of various types of anemia. As a series of safety studies on YHB216, we performed the local irritation test (dermal & ocular application) in male New Zealand White rabbits and micronucleus test in male ICR mice. In the skin irritation test, 0.5 ml of YHB216 10,000 IU/ml solution was applied to the back skin of rabbits for 24 hours and subsequent observation was performed. There was no induced response after the treatment and the primary irritation index (P.I.I.) was ''0''. In the eye irritation test, 0.1 ml of YHB216 10,000 IU/ml solution was instilled into the conjunctiva of the eye. No treatment-related reaction was observed at the cornea, iris, and conjunctiva. In the micronucleus test, YHB216 was administered intravenously to male mice (6 mice per group) at dose levels of 0, 6,250, 12,500, and 25,000 IU/kg. Bone marrow cells were collected at 24 hours after the treatment. YHB216 treated groups showed no significant difference in the P/N (polychromatic erythrocyte/normochromatic erythrocyte) ratio and in the number of micronucleated polychromatic erythrocyte compared with the control. In conclusion, YHB216 was found to be a non-irritating material up to 10,000 IU/ml in the local irritation test and to be a non-mutagen up to 25,000 IU/kg in the micronucleus test.
YHB6211(recombinant human granulocyte-colony stimulating factor)의 토끼에서 국소자극성에 관한연구
최연식(Yeon Shik Choi),안경규(Kyoung Kyu Ahn),전재현(Jae Hyeon Juhn),이종성(Jong Sung Lee),문병석(Byoung Seok Moon),유광현(Kwang Hyun You) 한국독성학회 1999 Toxicological Research Vol.15 No.2
Local irritation of YHB6211, a recombinant human granulocyte-colony stimulating factor, was assessed in male New Zealand White (NZW) rabbits by dermal and ocular application. In the skin irritation test, 0.5 ml of 0.03% YHB6211 aqueous solution was applied to the back skin of rabbits for 24 hours, and subsequent observation was performed. The solution did not induce any response after the treatment, and the primary irritation index (P.I.I.) of the compound was 0. In the eye irritation test, 0.1 ml of the same solution was instilled into the conjunctiva of the eye. No treatment related reactions were observed at the cornea, iris, and conjunctiva. Based on these results, 0.03% (w/v) YHB6211 solution could be considered as a non-irritating material.
조용현(Yong-Hyun Cho),유성원(Sung-Won Ryu),안경규(Kyung-Gyu Ahn) 한국지능시스템학회 2015 한국지능시스템학회논문지 Vol.25 No.4
본 논문에서는 모바일 환경에서 원격으로 창호시스템을 감시하고 제어하기 위한 새로운 관제시스템을 개발한다. 이를 위해 창호개폐기, 게이트웨이, 관제서버 시스템을 각각 설계·구현한다. 여기서 창호개폐기는 개폐를 위해 직류모터를 이용한 구동장치와 상태정보를 모니터링하고 개폐제어 정보를 전송하는 모션제어장치로 구성된다. 게이트웨이는 창호의 현재 상태정보와 제어정보를 전송하기 위한 유·무선 통신 인터페이스로 TCP/IP와 CDMA 프로토콜을 지원한다. 또한 관제서버는 창호 제어정보의 저장과 처리를 위한 프로그램, 다양한 상태메시지의 처리를 지원하기 위한 미들웨어, 그리고 개폐 상태를 감시하여 시스템을 원격제어하기 위한 DB로 구성된다. 특히 스마트폰과 같은 모바일환경을 지원하는 응용소프트웨어와 웹기반 사용자 인터페이스도 함께 개발되었다. PC 및 스마트폰 기반 개발된 창호 시스템의 시작품을 대상으로 동작성능, 환경영향, 구동 내구성, 그리고 동작오율 각각을 2개의 공인기관에서 시험한 결과, 우수한 성능이 있음을 확인하였다. This paper develops a new system for remotely monitoring and controlling the windows and doors in mobile environment. We design and implement the opening and shutting unit, the gateway, and the control server system, respectively. The opening and shutting unit consists of the driver using DC motor and the motion controller which monitors the state and transfers the control information. The gateway supports TCP/IP and CDMA protocol, which is the interface of wire and wireless communication for transferring the current state and control information. The control server consists of the program to store and process the control information, the middleware to support the processing of various state message, and DB for monitoring the state and remotely controlling the system. E specially, an application software and the Web-based user interface have also been developed to support the mobile environment. The operation performances, environment influences, driving persistences, and operation failure ratio, which are based on PC and smart-phone, have been tested in 2 authorized agencies. The test results show that the developed system has a superior performance.
YHB216 의 비글개에서 정맥내 단회 및 4 주 반복투여독성시험
장호송(Hu Song Zhang),정은용(Eun Yong Jung),신지순(Ji Soon Sin),안경규(Kyoung Kyu Ahn),최연식(Yeon Shik Choi),강종구(Jong Koo Kang),노용우(Yong Woo Roh),지형진(Hyeong Jin Ji),강민정(Min Joung Kang),이종욱(Jong Wook Lee) 한국응용약물학회 2002 Biomolecules & Therapeutics(구 응용약물학회지) Vol.10 No.1
N/A Recently, recombinant human erythropoietin (rHu-EPO) has been used to treat various types of anemia. YHB216 is a new rHu-EPO developed by Yuhan Research Institute. In this study, we investigated the single dose and 4-week repeated dose toxicity of YHB216 in Beagle dogs. In the single dose toxicity study, YHB216 was administered intravenously at single dose levels of 0 and 25,000 IU/㎏ to dogs (2 dogs/sex/ group). There were no treatment-related changes in survivals, clinical signs, body weight gain, hematological values, blood chemical values, and necropsy finding during experimental period. In the repeated dose toxicity study, YHB216 was administered intravenously to dogs for 4 weeks at the dose levels of 0, 100, 500, and 2,500 IU/㎏ (3 dogs/sex/group). There were no toxicologically significant changes in clinical signs, body weights, food and water consumptions, ophthalmoscopy, urinalysis and blood chemistry. There were increased values of red blood cell, hemoglobin, and hematocrit at all treated groups. Spleen revealed increased weight and extramedullary hematopoiesis at 500 IU/㎏ or more. These changes are all considered to be pharmacology-related effects and were recovered after 4-week recovery period. From these results, it is concluded that LD_50 value was above 25,000 IU/㎏ in the single dose toxicity study of YHB216 in dogs and the no observed adverse effect level (NOAEL) was 100 IU/㎏/day in the repeated dose toxicity study of YHB216 in dogs.
임신토끼에 있어서 새로운 Recombinant Human Granulocyte Colony - Stimulating Factor ( YHB6211 ) 의 배 , 태자 발생독성평가
황재식(Zai Zhi Huang),이수해(Su Hae Lee),신지순(Ji Soon Sin),신장우(Jang Woo Sin),최연식(Yeon Shik Choi),김대중(Dae Joong Kim),장호송(Hu Song Zhang),정은용(Eun Yong Jung),서동석(Dong Suk Seo),안경규(Kyoung Kyu Ahn),남상윤(Sang Yoon N 한국응용약물학회 2001 Biomolecules & Therapeutics(구 응용약물학회지) Vol.9 No.4
N/A YHB6211, a newly developed recombinant human granulocyte colonystimulating factor, was administered at dose levels of 0, 3, 15, and 75 ㎍/㎏/day intravenously to the pregnant New Zealand White rabbits (20 rabbits per group) during the organogenetic period, days 6 to 18 of gestation. All dams were subjected to Caesarian section on day 28 of gestation and their fetuses were examined for external, visceral, and skeletal abnormalities. No abnormalities in clinical signs, body weight changes, gross findings, mortality, and external appearance were found in all dams and fetuses exposed to 0, 3, and 15 ㎍/㎏/day of YHB6211. However, in the group treated with 75 ㎍/㎏/day of YHB6211, maternal body and uterine weights, fetal body weights and length, and the number of live fetuses were significantly decreased and further fetal mortality was remarkably increased. It is suggested that YHB6211 may have no side effect up to the dose level of 15 ㎍/㎏/day, and there would be no teratogenicity for fetuses of rabbits up to 75 ㎍/㎏/day even if it may have some toxic effects over 75 ㎍/㎏/day for dams and fetuses of rabbits.